GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.
Cursiefen C, Bock F, Horn FK, Kruse FE, Seitz B, Borderie V, Früh B, Thiel MA, Wilhelm F, Geudelin B, Descohand I, Steuhl KP, Hahn A, Meller D.
Cursiefen C, et al. Among authors: horn fk.
Ophthalmology. 2009 Sep;116(9):1630-7. doi: 10.1016/j.ophtha.2009.04.016. Epub 2009 Jul 29.
Ophthalmology. 2009.
PMID: 19643487
Clinical Trial.